Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics. (April 2014)

• Record Type: Journal Article
• Authors: Schreiner, Andreas; Lahaye, Marjolein; Peuskens, Joseph; Naber, Dieter; Dilbaz, Nesrin; Millet, Bruno; Franco, Manuel A; Rancans, Elmars; Turczynski, Jacek; Smeraldi, Enrico; Lara, Elsa; Neznanov, Nikolaj G
• Is Part Of: Expert opinion on pharmacotherapy. Volume 15:Number 5(2014)
• Page Start: 593
• Page End: 603
• Publication Date: 2014-04
• Subjects: Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2014.884071
• Languages: English
• ISSNs: 1465-6566

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Objective:</italic> </bold> This study explores relevant outcomes with flexibly dosed paliperidone extended-release (ER) in a real-world design.</p> <p> <bold> <italic>Research design and methods:</italic> </bold> Patients were recruited from 23 countries. Adults with non-acute schizophrenia (n = 1812), previously unsuccessfully treated with other oral antipsychotics, were transitioned to paliperidone ER and prospectively treated for 6 months.</p> <p> <bold> <italic>Main outcome measures:</italic> </bold> Primary efficacy outcome for patients switching for the main reason of lack of efficacy was ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) total scores. For patients switching for main reasons other than lack of efficacy, primary outcome was non-inferiority in efficacy compared with the previous medication.</p> <p> <bold> <italic>Results:</italic> </bold> Among the lack-of-efficacy group, 61% achieved a ≥ 20% improvement in PANSS total scores from baseline to endpoint. For switchers from other than the lack-of-efficacy group, efficacy maintenance after switching to paliperidone ER was confirmed. Clinically relevant and statistically significant symptomatic improvements occurred for each patient group based on main reason for switching.</p> <p> <bold> <italic>Conclusion:</italic> </bold> Paliperidone ER was well tolerated and associated with a meaningful clinical response in patients who switched from other oral antipsychotics, with insomnia and anxiety as most frequent side-effects.</p> </abstract>